Keep an eye on Altimmune (ALT).

After pulling back from about $15 to $8, it’s starting to pivot higher again. From its last traded price of $10.18, I’d like to see it retest $15 initially. It’s also working on an obesity drug, with good results, as well. Citing data from its MOMENTUM trial, the company said pemvidutide, led to weight loss while preserving lean mass.

Markets are most active at two specific times of the day. Click here to see which is best for entering trades.

“At the 2.4 mg dose — the highest tested — mean weight loss of 15.6% was seen at week 48. More than 30% of patients in this cohort achieved at least 20% weight loss. Results further showed that greater weight loss was seen with higher doses of the peptide-based GLP-1/glucagon dual receptor agonist,” as noted by Seeking Alpha.


Ian Cooper